MINERVA NEUROSCIENCES INC (NERV) Stock Price, Forecast & Analysis
NASDAQ:NERV • US6033802058
NERV Key Statistics, Chart & Performance
The current stock price of NERV is 6.45 USD. In the past month the price increased by 44.94%. In the past year, price increased by 254.4%.
NERV Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NERV. When comparing the yearly performance of all stocks, NERV is one of the better performing stocks in the market, outperforming 98.69% of all stocks.
NERV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NERV. Both the profitability and financial health of NERV have multiple concerns.
NERV Financial Highlights
Over the last trailing twelve months NERV reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS increased by 31.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.93% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NERV Forecast & Estimates
7 analysts have analysed NERV and the average price target is 4.59 USD. This implies a price decrease of -28.84% is expected in the next year compared to the current price of 6.45.
NERV Ownership
NERV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.04 | 411.552B | ||
| AMGN | AMGEN INC | 16.57 | 201.047B | ||
| GILD | GILEAD SCIENCES INC | 17.41 | 192.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 121.106B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.08 | 83.892B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.65 | 43.941B | ||
| INSM | INSMED INC | N/A | 32.101B | ||
| NTRA | NATERA INC | N/A | 29.393B | ||
| BIIB | BIOGEN INC | 12.86 | 28.709B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 20.773B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NERV
Company Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Company Info
MINERVA NEUROSCIENCES INC
1601 Trapelo Road, Suite 284
Waltham MASSACHUSETTS 02451 US
CEO: Remy Luthringer
Employees: 8
Phone: 16176007373
MINERVA NEUROSCIENCES INC / NERV FAQ
Can you describe the business of MINERVA NEUROSCIENCES INC?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
What is the stock price of MINERVA NEUROSCIENCES INC today?
The current stock price of NERV is 6.45 USD. The price increased by 2.87% in the last trading session.
Does MINERVA NEUROSCIENCES INC pay dividends?
NERV does not pay a dividend.
What is the ChartMill rating of MINERVA NEUROSCIENCES INC stock?
NERV has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of MINERVA NEUROSCIENCES INC (NERV)?
MINERVA NEUROSCIENCES INC (NERV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.32).
Can you provide the market cap for MINERVA NEUROSCIENCES INC?
MINERVA NEUROSCIENCES INC (NERV) has a market capitalization of 279.09M USD. This makes NERV a Micro Cap stock.